Edition:
United States

Dova Pharmaceuticals Inc (DOVA.OQ)

DOVA.OQ on NASDAQ Stock Exchange Global Market

31.21USD
15 Dec 2017
Change (% chg)

$-1.22 (-3.76%)
Prev Close
$32.43
Open
$32.30
Day's High
$32.43
Day's Low
$31.13
Volume
460,065
Avg. Vol
41,273
52-wk High
$32.74
52-wk Low
$16.98

Latest Key Developments (Source: Significant Developments)

Dova Pharmaceuticals Announces FDA Acceptance Of The Avatrombopag New Drug Application With Priority Review
Monday, 27 Nov 2017 04:05pm EST 

Nov 27 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE AVATROMBOPAG NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW.DOVA PHARMACEUTICALS INC - PDUFA GOAL DATE FOR AN FDA DECISION IS MAY 21, 2018 FOR NDA​.  Full Article

Dova Pharmaceuticals reports third quarter results
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Dova Pharmaceuticals Inc :Dova Pharmaceuticals reports third quarter 2017 operating and financial results.Dova Pharmaceuticals Inc - qtrly ‍net loss per share, basic and diluted $0.38​.  Full Article

Dova Pharmaceuticals announces New Drug Application submission to FDA
Friday, 22 Sep 2017 07:00am EDT 

Sept 22 (Reuters) - Dova Pharmaceuticals Inc :Dova Pharmaceuticals announces New Drug Application submission to FDA for avatrombopag, a second generation thrombopoietin receptor agonist.Dova Pharmaceuticals Inc - ‍in both trials, avatrombopag met primary and secondary efficacy endpoints with high statistical significance​.Dova pharmaceuticals inc - ‍submission of a New Drug Application to U.S. Food and Drug Administration for avatrombopag​.  Full Article

Dova Pharmaceuticals qtrly net loss per share, basic and diluted $0.32
Thursday, 10 Aug 2017 04:05pm EDT 

Aug 10 (Reuters) - Dova Pharmaceuticals Inc :Dova Pharmaceuticals reports second quarter 2017 operating and financial results.Qtrly net loss per share, basic and diluted $0.32.  Full Article

Perceptive Advisors reports 6.8 pct passive stake in Dova Pharma
Tuesday, 1 Aug 2017 09:17am EDT 

Aug 1 (Reuters) - Perceptive Advisors Llc::Perceptive Advisors Llc reports a 6.8 pct passive stake in Dova Pharmaceuticals Inc <<>> as of July 5 - SEC filing.  Full Article

Dova Pharmaceuticals shares open at $19.25 in debut vs IPO price of $17/shr
Thursday, 29 Jun 2017 10:25am EDT 

June 29 (Reuters) - :Dova Pharmaceuticals Inc shares open at $19.25 in debut on the Nasdaq versus IPO price of $17.00.  Full Article

Dova Pharmaceuticals prices IPO at $17/share
Wednesday, 28 Jun 2017 10:36pm EDT 

June 28 (Reuters) - Dova Pharmaceuticals Inc : :Dova Pharmaceuticals Inc Announces pricing of initial public offering.Says initial public offering of 4.42 million common shares priced at $17.00 per share.  Full Article

Dova Pharma sees IPO to be priced between $15 and $17/shr
Monday, 19 Jun 2017 06:27am EDT 

June 19 (Reuters) - Dova Pharmaceuticals Inc ::Dova Pharmaceuticals Inc sees IPO of upto 4.06 million shares of common stock to be priced between $15 and $17 per share - SEC filing.Dova Pharmaceuticals Inc says intends to use about $19.0 million of IPO proceeds to fund commercialization of Avatrombopag.Dova Pharmaceuticals Inc says intends to use about $21 million of IPO proceeds to fund clinical trials of Avatrombopag for additional indications.Dova Pharmaceuticals Inc says intends to use about $30 million of IPO proceeds as repayment to EISAI of a portion of our obligations under the EISAI note.  Full Article

BRIEF-Dova Pharmaceuticals Announces FDA Acceptance Of The Avatrombopag New Drug Application With Priority Review

* DOVA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE AVATROMBOPAG NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW